CTCs, cfDNA and Tissue Biopsies: A Comparison

CTCs, cfDNA and Tissue Biopsies: A Comparison

Very small traces of DNA, and the development of tools to detect them, could revolutionize cancer diagnostics and resulting treatment. Circulating tumor DNA (ctDNA, a subset of cell-free DNA) and circulating tumor cells (CTCs) are shed by tumors into the blood and other body fluids. Two technologies in particular, next-generation sequencing (NGS) and digital PCR (dPCR), have allowed scientists to overcome the extremely low concentrations of these analytes. This article discusses the developments and compares the various approaches.


Roche Closes 454 But Company Not Out of Next-Gen Yet

Roche Closes 454 But Company Not Out of Next-Gen Yet

In Kalorama’s report, " Next Generation Sequencing Trends ," our survey discovered that while 75% of labs had an Illumina sequencer, less than a third had a Roche brand sequencer and it was not generally part of our surveyed labs’ purchasing plans. Roche’s recent move confirms our findings and admists market reality.

This month, Roche announced the closing its wholly-owned subsidiary 454 Life Sciences and laying off the company’s 130 employees. They will keep making sequencers, however, throug...